Growth in life sciences is not simply a question of adding more people. It is about having the right capabilities, at the right time, to overcome the next constraint standing between the business and its strategy.

As life science companies move through discovery, clinical development, regulatory milestones and commercialisation, their organisational requirements can change dramatically.

Yet one of the most common mistakes we see is treating future organisational needs as though they are immediate vacancies.

A company raises capital, enters the clinic, acquires a new platform or prepares for commercial launch — and the instinct is often to build the organisation that the business will eventually need.

The problem is that the future organisation is rarely as predictable as the current strategy suggests.

Build for the next requirement — not the imagined end state

At each stage of a life science company's development, different capabilities become critical.

Early-stage businesses may need scientific judgement, portfolio discipline and capital efficiency. As programmes enter clinical development, the emphasis shifts towards clinical operations, regulatory strategy, CMC, quality, financing and governance.

Approaching commercialisation brings another set of requirements: medical affairs, market access, pharmacovigilance, supply chain, commercial leadership and launch execution.

The mistake is to assume that every capability needs to become a permanent layer of the organisation immediately.

The more useful question for boards and leadership teams is:

What must we be able to do next?

That question changes the conversation from how many people should we hire? to what capability does the business require to reach its next value-creating milestone?

The right leader for today may not be the right leader for tomorrow

Organisational evolution also means recognising that leadership mandates change.

The executive who successfully takes a company through one phase of its development may not necessarily be the person best equipped to lead the next.

That is not a reflection on the individual. The mandate has changed.

A leader who is highly effective in taking a company into the clinic may have a very different challenge when the business begins building a global commercial organisation.

Boards can understandably favour continuity. But continuity should not become an excuse for maintaining roles, structures or responsibilities that no longer reflect the strategic requirement.

The organisation must evolve alongside the business.

Fractional and interim leadership can provide strategic flexibility

This is where fractional and interim leadership can play an important role.

Not every capability needs to become permanent headcount from day one.

For companies navigating an inflection point, bringing in experienced leadership for a defined period can provide immediate expertise while allowing the organisation to establish what the long-term requirement actually looks like.

This can be particularly valuable when a business is approaching a major clinical, regulatory or commercial milestone but the eventual organisational structure remains uncertain.

The objective is not to delay investment.

It is to match the employment model to the maturity and certainty of the requirement.

At RSA, this principle is central to our approach to leadership on demand. We help life science organisations access experienced operators when they need them — whether to bridge a leadership gap, accelerate a critical milestone or provide specialist expertise during a period of change.

Benchmarks should inform decisions — not make them

Headcount benchmarks can be useful. They provide boards and investors with a reference point and can highlight organisations that appear significantly over- or under-resourced.

But they should never become a formula.

Two companies generating the same revenue can have radically different organisational requirements.

One might operate through extensive outsourcing, focus on a concentrated geography and have a relatively simple portfolio. Another might be managing multiple launches, significant development activity, manufacturing responsibilities and complex global regulatory and medical requirements.

Revenue alone cannot tell you what an organisation needs.

The more useful question is whether the organisation is appropriately resourced for the work it actually has to perform.

Every significant hire should answer three questions

Before approving a major appointment or building a new team, boards should be able to answer:

1. What milestone, constraint or material risk will this capability address over the next 12–24 months?

2. What evidence tells us that the workload or complexity is genuinely arriving?

3. Does this capability need to become permanent internal headcount now?

These questions create a useful discipline around organisational growth.

They also recognise that capability does not have to exist in only two forms — permanent employee or nothing.

Depending on the circumstances, expertise can be built internally, accessed externally, or introduced for a defined period.

What matters is that the model reflects the work the company needs to do, rather than the size of the organisation it hopes eventually to become.

Growth should create leverage — not simply overhead

The strongest organisations are not necessarily those with the largest leadership teams or the most impressive organisational charts.

They are the organisations that understand:

• which capabilities they need now;

• which capabilities they will need next;

• which capabilities can remain external until the requirement becomes clearer; and

• where existing roles and mandates need to evolve.

Headcount should therefore be viewed as an outcome of strategy — not a proxy for it.

A growing employee base does not, by itself, demonstrate growth.

Real organisational growth is the ability to reach the next value-creating milestone without introducing unnecessary cost, complexity or execution risk.

Preparing for the inflection point

There is an important balance to strike.

Waiting until a capability gap becomes critical is rarely the answer. Certain expertise must be secured well ahead of a clinical, regulatory or commercial milestone because experienced leadership cannot always be found and integrated overnight.

The answer is therefore neither to build the entire future organisation years in advance nor to wait until the need becomes urgent.

It is to understand what the business is likely to need next, maintain access to the right talent and expertise, and be ready to act when the evidence says the time is right.

That is where a strong leadership network becomes strategically valuable.

At RSA, we work with life science boards and leadership teams through precisely these inflection points — combining executive search, fractional and interim leadership, and real-world industry experience to help organisations access the capabilities they need as their requirements evolve.

Read the full perspective

This article summarises the central argument from Nick Stephens, Executive Chairman of The RSA Group, in his recent Pharmaphorum article:

“Headcount is not a growth strategy.”

For the full discussion — including organisational benchmarks, revenue-per-employee considerations and a deeper look at how boards should approach hiring through different stages of growth — read Nick's full article on Pharmaphorum.

→ Read “Headcount is not a growth strategy” on Pharmaphorum